<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15205116</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0193-1857</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>287</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Two TTX-resistant Na+ currents in mouse colonic dorsal root ganglia neurons and their role in colitis-induced hyperexcitability.</ArticleTitle>
            <Pagination>
                <MedlinePgn>G845-55</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The composition of Na+ currents in dorsal root ganglia (DRG) neurons depends on their neuronal phenotype and innervation target. Two TTX-resistant (TTX-R) Na+ currents [voltage-gated Na channels (Nav)] have been described in small DRG neurons; one with slow inactivation kinetics (Nav1.8) and the other with persistent kinetics (Nav1.9), and their modulation has been implicated in inflammatory pain. This has not been studied in neurons projecting to the colon. This study examined the relative importance of these currents in inflammation-induced changes in a mouse model of inflammatory bowel disease. Colonic sensory neurons were retrogradely labeled, and colitis was induced by instillation of trinitrobenzenesulfonic acid (TNBS) into the lumen of the distal colon. Seven to ten days later, immunohistochemical properties were characterized in controls, and whole cell recordings were obtained from small (&lt;40 pF) labeled DRG neurons from control and TNBS animals. Most neurons exhibited both fast TTX-sensitive (TTX-S)- and slow TTX-R-inactivating Na+ currents, but persistent TTX-R currents were uncommon (&lt;15%). Most labeled neurons were CGRP (79%), tyrosine kinase A (trkA) (84%) immunoreactive, but only a small minority bind IB4 (14%). TNBS-colitis caused ulceration, thickening of the colon and significantly increased neuronal excitability. The slow TTX-R-inactivating Na current density (Nav1.8) was significantly increased, but other Na currents were unaffected. Most small mouse colonic sensory neurons are CGRP, trkA immunoreactive, but not isolectin B4 reactive and exhibit fast TTX-S, slow TTX-R, but not persistent TTX-R Na+ currents. Colitis-induced hyperexcitability is associated with increased slow TTX-R (Nav1.8) Na+ current. Together, these findings suggest that colitis alters trkA-positive neurons to preferentially increase slow TTX-R Na+ (Nav1.8) currents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Beyak</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastrointestinal Diseases Research Unit, Queen's University, Kingston, Ontario, Canada K7L 5G2 .</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramji</LastName>
                    <ForeName>Noor</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krol</LastName>
                    <ForeName>Karmen M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawaja</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vanner</LastName>
                    <ForeName>Stephen J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>06</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
            <NlmUniqueID>100901227</NlmUniqueID>
            <ISSNLinking>0193-1857</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D037102">Lectins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D062559">NAV1.8 Voltage-Gated Sodium Channel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D062558">NAV1.9 Voltage-Gated Sodium Channel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C568318">Scn10a protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C491885">Scn11a protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4368-28-9</RegistryNumber>
                <NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>83652-28-2</RegistryNumber>
                <NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9NEZ333N27</RegistryNumber>
                <NameOfSubstance UI="D012964">Sodium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000779">Anesthetics, Local</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015740">Calcitonin Gene-Related Peptide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003106">Colon</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000294">innervation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005727">Ganglia, Spinal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007700">Kinetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D037102">Lectins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008564">Membrane Potentials</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008815">Mice, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062559">NAV1.8 Voltage-Gated Sodium Channel</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062558">NAV1.9 Voltage-Gated Sodium Channel</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009475">Neurons, Afferent</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009479">Neuropeptides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009619">Nociceptors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020917">Receptor, trkA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012964">Sodium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015222">Sodium Channels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013779">Tetrodotoxin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2004</Year>
                <Month>Jun</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15205116</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpgi.00154.2004</ArticleId>
            <ArticleId IdType="pii">00154.2004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17112560</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>12</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0041-008X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>217</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Dec</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Developmental toxicity of 4-ring polycyclic aromatic hydrocarbons in zebrafish is differentially dependent on AH receptor isoforms and hepatic cytochrome P4501A metabolism.</ArticleTitle>
            <Pagination>
                <MedlinePgn>308-21</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Polycyclic aromatic hydrocarbons (PAHs) derived from fossil fuels are ubiquitous contaminants and occur in aquatic habitats as highly variable and complex mixtures of compounds containing 2 to 6 rings. For aquatic species, PAHs are generally accepted as acting through either of two modes of action: (1) &quot;dioxin-like&quot; toxicity mediated by activation of the aryl hydrocarbon receptor (AHR), which controls a battery of genes involved in PAH metabolism, such as cytochrome P4501A (CYP1A) and (2) &quot;nonpolar narcosis&quot;, in which tissue uptake is dependent solely on hydrophobicity and toxicity is mediated through non-specific partitioning into lipid bilayers. As part of a systematic analysis of mechanisms of PAH developmental toxicity in zebrafish, we show here that three tetracyclic PAHs (pyrene, chrysene, and benz[a]anthracene) activate the AHR pathway tissue-specifically to induce distinct patterns of CYP1A expression. Using morpholino knockdown of ahr1a, ahr2, and cyp1a, we show that distinct embryolarval syndromes induced by exposure to two of these compounds are differentially dependent on tissue-specific activation of AHR isoforms or metabolism by CYP1A. Exposure of embryos with and without circulation (silent heart morphants) resulted in dramatically different patterns of CYP1A induction, with circulation required to deliver some compounds to internal tissues. Therefore, biological effects of PAHs cannot be predicted simply by quantitative measures of AHR activity or a compound's hydrophobicity. These results indicate that current models of PAH toxicity in fish are greatly oversimplified and that individual PAHs are pharmacologically active compounds with distinct and specific cellular targets.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Incardona</LastName>
                    <ForeName>John P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ecotoxicology and Environmental Fish Health Program, Environmental Conservation Division, Northwest Fisheries Science Center, 2725 Montlake Blvd E, Seattle, WA 98112, USA. john.incardona@noaa.gov</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Day</LastName>
                    <ForeName>Heather L</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collier</LastName>
                    <ForeName>Tracy K</ForeName>
                    <Initials>TK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scholz</LastName>
                    <ForeName>Nathaniel L</ForeName>
                    <Initials>NL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001551">Benz(a)Anthracenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002911">Chrysenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011084">Polycyclic Hydrocarbons, Aromatic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011721">Pyrenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018336">Receptors, Aryl Hydrocarbon</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014874">Water Pollutants, Chemical</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>084HCM49PT</RegistryNumber>
                <NameOfSubstance UI="C031180">chrysene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9E0T7WFW93</RegistryNumber>
                <NameOfSubstance UI="C030984">pyrene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>C5PLF6152K</RegistryNumber>
                <NameOfSubstance UI="C030935">benz(a)anthracene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000014">Abnormalities, Drug-Induced</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001551">Benz(a)Anthracenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002911">Chrysenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004625">Embryo, Nonmammalian</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004790">Enzyme Induction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006330">Heart Defects, Congenital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007814">Larva</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009025">Morpholines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016376">Oligonucleotides, Antisense</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011084">Polycyclic Hydrocarbons, Aromatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011721">Pyrenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018336">Receptors, Aryl Hydrocarbon</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014874">Water Pollutants, Chemical</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(06)00344-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2006.09.018</ArticleId>
            <ArticleId IdType="pubmed">17112560</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2055368</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0272-0590</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1991</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Fundamental and applied toxicology : official journal of the Society of Toxicology</Title>
                <ISOAbbreviation>Fundam Appl Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modulation of 2,3,7,8-tetrachlorodibenzo-p-dioxin and phenobarbital-induced promotion of hepatocarcinogenesis in rats by the type of diet and vitamin A deficiency.</ArticleTitle>
            <Pagination>
                <MedlinePgn>375-91</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This study was undertaken to investigate the influence of dietary vitamin A deficiency and type of diet on tetrachlorodibenzo-p-dioxin (TCDD)- and phenobarbital-induced liver tumor promotion in rats. Female Sprague-Dawley rats were partially hepatectomized and subsequently initiated with nitrosodiethylamine. One week later the rats were allocated to five different dietary regimens for the duration of the study: three purified (casein-based) diets containing 200, 1200, and 10000 IU vitamin A per kilogram, respectively, and two conventional (cereal-based) rat diets containing 2000 and 14000 IU vitamin A per kilogram, respectively. After an additional 4 weeks, groups of rats on each dietary regimen were started on one of four different promoter treatments: 0.07 micrograms TCDD/kg/week (sc); 0.7 micrograms TCDD/kg/week (sc); 500 ppm phenobarbital in the drinking water or vehicle only (arachis oil, sc). The study was terminated after 16 weeks of promoter treatment. Sections of liver were stained for gamma-glutamyltranspeptidase (GGT) activity and GGT-positive altered hepatic foci (AHF) were evaluated by stereological methods. All factors studied (TCDD, phenobarbital, dietary vitamin A content, and the type of diet) were shown to influence AHF development significantly. As expected, TCDD and phenobarbital enhanced foci development. Vitamin A deficiency enhanced foci development in its own right and increased the TCDD-induced response markedly. Dietary vitamin A content did not modulate phenobarbital promotion of AHF in the same manner. The enhancement of TCDD-induced effects on foci development by vitamin A deprivation was accompanied by an increased incidence of histological changes marking degeneration in the liver (e.g., oval cell hyperplasia) and accentuation of other TCDD-related toxic responses. In addition, the groups of rats maintained on the cereal-based diets and subjected to the various promoter/vitamin A regimens exhibited significantly higher AHF incidence as compared to correspondingly treated rats fed the purified, casein-based diets. In conclusion, vitamin A deficiency alone may promote hepatocarcinogenesis and enhance the promoting effect of TCDD treatment. However, TCDD-induced depletion of hepatic vitamin A stores was not implicated as a major cause of promotion by TCDD. Nevertheless, vitamin A deficiency brought about by TCDD alone may well act as a promotive stimulus concertedly with an as yet unidentified cellular mechanism in TCDD-induced liver tumor promotion. The differential effects of the two types of diets recorded in the study remain undocumented.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Flodström</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Busk</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kronevi</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahlborg</LastName>
                    <ForeName>U G</ForeName>
                    <Initials>UG</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Fundam Appl Toxicol</MedlineTA>
            <NlmUniqueID>8200838</NlmUniqueID>
            <ISSNLinking>0272-0590</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>11103-57-4</RegistryNumber>
                <NameOfSubstance UI="D014801">Vitamin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9035-51-2</RegistryNumber>
                <NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DO80M48B6O</RegistryNumber>
                <NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.-</RegistryNumber>
                <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D000637">Transaminases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003577">Cytochrome P-450 Enzyme System</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004032">Diet</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008114">Liver Neoplasms, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010088">Oxidoreductases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000637">Transaminases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014801">Vitamin A</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014802">Vitamin A Deficiency</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2055368</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17460324</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1062-3264</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of critical care : an official publication, American Association of Critical-Care Nurses</Title>
                <ISOAbbreviation>Am. J. Crit. Care</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Iatrogenic sick sinus syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>294-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Keller</LastName>
                    <ForeName>Kathryn Buchanan</ForeName>
                    <Initials>KB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton, FL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lemberg</LastName>
                    <ForeName>Louis</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Crit Care</MedlineTA>
            <NlmUniqueID>9211547</NlmUniqueID>
            <ISSNLinking>1062-3264</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E90NZP2L9U</RegistryNumber>
                <NameOfSubstance UI="D004074">Digitoxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>N</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004074">Digitoxin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007049">Iatrogenic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012804">Sick Sinus Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">16/3/294</ArticleId>
            <ArticleId IdType="pubmed">17460324</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3083914</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0267-0623</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>292</Volume>
                    <Issue>6524</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>Mar</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British medical journal (Clinical research ed.)</Title>
                <ISOAbbreviation>Br Med J (Clin Res Ed)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cholestatic jaundice caused by ethambutol.</ArticleTitle>
            <Pagination>
                <MedlinePgn>866</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gulliford</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mackay</LastName>
                    <ForeName>A D</ForeName>
                    <Initials>AD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prowse</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Med J (Clin Res Ed)</MedlineTA>
            <NlmUniqueID>8302911</NlmUniqueID>
            <ISSNLinking>0267-0623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>8G167061QZ</RegistryNumber>
                <NameOfSubstance UI="D004977">Ethambutol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Q J Med. 1984 Autumn;53(212):497-510</RefSource>
                <PMID Version="1">6515003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 1972 Jun;61(6):579-82</RefSource>
                <PMID Version="1">4260668</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002779">Cholestasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004977">Ethambutol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014397">Tuberculosis, Pulmonary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1339973</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>3</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3083914</ArticleId>
            <ArticleId IdType="pmc">PMC1339973</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11588001</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>10</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1073-449X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>164</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Sep</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of respiratory and critical care medicine</Title>
                <ISOAbbreviation>Am. J. Respir. Crit. Care Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Restoring effects of vitamin A on surfactant synthesis in nitrofen-induced congenital diaphragmatic hernia in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1083-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Congenital diaphragmatic hernia (CDH) is a major cause of refractory respiratory failure in the newborn. Besides pulmonary hypoplasia, the pathophysiology of CDH also includes surfactant deficiency. Vitamin A (vit A) is important for various aspects of lung development. We hypothesized that antenatal treatment with vit A would stimulate lung surfactant synthesis in experimental CDH induced in rats by maternal ingestion of the herbicide nitrofen (2,4-dichloro-phenyl-p-nitrophenyl-ether) on Day 12. Fetuses were assigned to six experimental groups: (1) controls from rats that received olive oil, the vehicle; (2) fetuses from rats that received olive oil on Day 12 and vit A orally (15,000 IU) on Day 14; (3) nitrofen (N)-exposed fetuses without diaphragmatic hernia (N/no DH); (4) N/no DH from rats given vit A on Day 14; (5 ) nitrofen-exposed fetuses with DH (N/+DH); (6) N/+DH from rats given vit A on Day 14. Fetuses were delivered by C-section at Day 21. Lung DNA content was lowered in the nitrofen group as compared with the controls group, but increased by subsequent vit A treatment. Lung surfactant disaturated phosphatidylcholine was reduced in the N/+DH group and restored to control level by vit A. The expression level of surfactant proteins (SP) -A and -C was decreased in vit A-treated control rats and in nitrofen-exposed fetuses with or without DH. Vit A restored SP-A and -C mRNA expression to control levels in N/+DH. SP-B expression was lowered in N/no DH and increased by vit A in this group. The proportion of type II cells assessed by SP-B immunolabeling was lowered in N/+DH and restored by vit A treatment. We conclude that antenatal treatment with vit A restores lung maturation in nitrofen-induced hypoplastic lungs with CDH. These findings point out vit A as a potential therapeutical agent for correcting surfactant deficiency in CDH.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thébaud</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Réanimation Néonatale-UPRES 2704, Hôpital Antoine Béclère, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, France. bthebaud@ualberta.ca</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barlier-Mur</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chailley-Heu</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henrion-Caude</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tibboel</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dinh-Xuan</LastName>
                    <ForeName>A T</ForeName>
                    <Initials>AT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourbon</LastName>
                    <ForeName>J R</ForeName>
                    <Initials>JR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Respir Crit Care Med</MedlineTA>
            <NlmUniqueID>9421642</NlmUniqueID>
            <ISSNLinking>1073-449X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006540">Herbicides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010647">Phenyl Ethers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011663">Pulmonary Surfactants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11103-57-4</RegistryNumber>
                <NameOfSubstance UI="D014801">Vitamin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1836-75-5</RegistryNumber>
                <NameOfSubstance UI="C007350">nitrofen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-49-2</RegistryNumber>
                <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015152">Blotting, Northern</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002855">Chromatography, Thin Layer</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004247">DNA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005333">Fetus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005865">Gestational Age</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006540">Herbicides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006548">Hernia, Diaphragmatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D065630">Hernias, Diaphragmatic, Congenital</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008168">Lung</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010647">Phenyl Ethers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010713">Phosphatidylcholines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011663">Pulmonary Surfactants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014801">Vitamin A</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>10</Month>
                <Day>6</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>10</Month>
                <Day>6</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11588001</ArticleId>
            <ArticleId IdType="doi">10.1164/ajrccm.164.6.2010115</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4454746</PMID>
        <DateCreated>
            <Year>1975</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1975</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0048-4733</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1974</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of the Medical Section of the Polish Academy of Sciences</Title>
                <ISOAbbreviation>Ann Med Sect Pol Acad Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ultrastructural changes in kidney glomeruli in daunomycin nephrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>155-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Walski</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>POLAND</Country>
            <MedlineTA>Ann Med Sect Pol Acad Sci</MedlineTA>
            <NlmUniqueID>7505203</NlmUniqueID>
            <ISSNLinking>0048-4733</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>ZS7284E0ZP</RegistryNumber>
                <NameOfSubstance UI="D003630">Daunorubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001485">Basement Membrane</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003630">Daunorubicin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007678">Kidney Glomerulus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009401">Nephrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1974</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1974</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1974</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4454746</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4273180</PMID>
        <DateCreated>
            <Year>1974</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1974</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-9150</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <MedlineDate>1974 Mar-Apr</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Atherosclerosis</Title>
                <ISOAbbreviation>Atherosclerosis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pathophysiologic effects of pre-existing hypertension on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>161-84</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wexler</LastName>
                    <ForeName>B C</ForeName>
                    <Initials>BC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NETHERLANDS</Country>
            <MedlineTA>Atherosclerosis</MedlineTA>
            <NlmUniqueID>0242543</NlmUniqueID>
            <ISSNLinking>0021-9150</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7647-14-5</RegistryNumber>
                <NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.1.1.27</RegistryNumber>
                <NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.1</RegistryNumber>
                <NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.2</RegistryNumber>
                <NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.3.2</RegistryNumber>
                <NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L628TT009W</RegistryNumber>
                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000410">Alanine Transaminase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045930">Anabolic Agents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001161">Arteriosclerosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001219">Aspartate Aminotransferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001806">Blood Urea Nitrogen</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003402">Creatine Kinase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005230">Fatty Acids, Nonesterified</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006977">Hypertension, Renal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D007545">Isoproterenol</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007770">L-Lactate Dehydrogenase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009392">Nephrectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1974</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1974</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1974</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4273180</ArticleId>
            <ArticleId IdType="pii">0021-9150(74)90052-5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22825968</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7330</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of assisted reproduction and genetics</Title>
                <ISOAbbreviation>J. Assist. Reprod. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1057-65</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10815-012-9825-8</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To detect expression of bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) in oocytes, and their receptor type 2 receptor for BMPs (BMPR2) in cumulus cells in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF), and determine if BMPR2, BMP15, and GDF9 expression correlate with hyperandrogenism in FF of PCOS patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Prospective case-control study. Eighteen MII-oocytes and their respective cumulus cells were obtained from 18 patients with PCOS, and 48 MII-oocytes and cumulus cells (CCs) from 35 controls, both subjected to controlled ovarian hyperstimulation (COH), and follicular fluid (FF) was collected from small (10-14 mm) and large (&gt;18 mm) follicles. RNeasy Micro Kit (Qiagen) was used for RNA extraction and gene expression was quantified in each oocyte individually and in microdissected cumulus cells from cumulus-oocyte complexes retrieved from preovulatory follicles using qRT-PCR. Chemiluminescence and RIA assays were used for hormone assays.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">BMP15 and GDF9 expression per oocyte was higher among women with PCOS than the control group. A positive correlation was found between BMPR2 transcripts and hyperandrogenism in FF of PCOS patients. Progesterone values in FF were lower in the PCOS group.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We inferred that BMP15 and GDF9 transcript levels increase in mature PCOS oocytes after COH, and might inhibit the progesterone secretion by follicular cells in PCOS follicles, preventing premature luteinization in cumulus cells. BMPR2 expression in PCOS cumulus cells might be regulated by androgens.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>de Resende</LastName>
                    <ForeName>Luciana Ochuiuto Teixeira</ForeName>
                    <Initials>LO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Obstetrics - Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vireque</LastName>
                    <ForeName>Alessandra Aparecida</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santana</LastName>
                    <ForeName>Laura Ferreira</ForeName>
                    <Initials>LF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreno</LastName>
                    <ForeName>Daniel Antunes</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Sá Rosa e Silva</LastName>
                    <ForeName>Ana Carolina Japur</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferriani</LastName>
                    <ForeName>Rui Alberto</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scrideli</LastName>
                    <ForeName>Carlos Alberto</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reis</LastName>
                    <ForeName>Rosana Maria</ForeName>
                    <Initials>RM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Assist Reprod Genet</MedlineTA>
            <NlmUniqueID>9206495</NlmUniqueID>
            <ISSNLinking>1058-0468</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055430">Bone Morphogenetic Protein 15</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C525897">GDF9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055429">Growth Differentiation Factor 9</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4G7DS2Q64Y</RegistryNumber>
                <NameOfSubstance UI="D011374">Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="C498218">BMPR2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="D052006">Bone Morphogenetic Protein Receptors, Type II</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod Update. 2009 May-Jun;15(3):297-307</RefSource>
                <PMID Version="1">19261627</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2008 Aug;90(2):447-9</RefSource>
                <PMID Version="1">17905236</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2010 Jun;94(1):261-7</RefSource>
                <PMID Version="1">19376510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Biomed Online. 2010 Jul;21(1):109-17</RefSource>
                <PMID Version="1">20427239</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Hum Reprod. 2010 Aug;16(8):531-8</RefSource>
                <PMID Version="1">20435608</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2010 Nov;94(6):2228-33</RefSource>
                <PMID Version="1">20171618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Histol. 2010 Dec;41(6):325-32</RefSource>
                <PMID Version="1">20857181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Biomed Online. 2011 Jul;23(1):77-80</RefSource>
                <PMID Version="1">21561809</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2011 Aug;96(2):464-8</RefSource>
                <PMID Version="1">21669410</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2011 Aug;96(8):E1246-54</RefSource>
                <PMID Version="1">21632818</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Metabolism. 2011 Nov;60(11):1511-4</RefSource>
                <PMID Version="1">22014425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Zhonghua Nan Ke Xue. 2013 May;19(5):414-7</RefSource>
                <PMID Version="1">23757962</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 2000 Feb;62(2):370-7</RefSource>
                <PMID Version="1">10642575</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2000 Nov;74(5):976-9</RefSource>
                <PMID Version="1">11056243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2000 Dec 15;275(50):39523-8</RefSource>
                <PMID Version="1">10998422</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Endocrinol Metab. 2000 Jul;11(5):193-8</RefSource>
                <PMID Version="1">10856922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>
                <PMID Version="1">11846609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2002 Mar;87(3):1337-44</RefSource>
                <PMID Version="1">11889206</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2002 Jun;87(6):2849-56</RefSource>
                <PMID Version="1">12050262</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Best Pract Res Clin Endocrinol Metab. 2002 Jun;16(2):263-72</RefSource>
                <PMID Version="1">12064892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Jan 3;278(1):304-10</RefSource>
                <PMID Version="1">12419820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Biomed Online. 2003 Mar;6(2):181-4</RefSource>
                <PMID Version="1">12675997</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Jul 18;278(29):26380-90</RefSource>
                <PMID Version="1">12734205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 2003 Aug;69(2):725-32</RefSource>
                <PMID Version="1">12700191</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2004 Jan;81(1):19-25</RefSource>
                <PMID Version="1">14711538</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Rev. 2004 Feb;25(1):72-101</RefSource>
                <PMID Version="1">14769828</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2004 Mar;18(3):653-65</RefSource>
                <PMID Version="1">14684852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Reprod Immunol. 2004 Aug;63(1):51-60</RefSource>
                <PMID Version="1">15284005</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Endocrinol. 2004 Aug;33(1):59-72</RefSource>
                <PMID Version="1">15291743</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 1995 Aug;10(8):2125-35</RefSource>
                <PMID Version="1">8567853</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1996 Oct 10;383(6600):531-5</RefSource>
                <PMID Version="1">8849725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 1999 Aug;84(8):2951-6</RefSource>
                <PMID Version="1">10443703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2005 Apr 29;234(1-2):67-73</RefSource>
                <PMID Version="1">15836954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reproduction. 2006 Mar;131(3):545-53</RefSource>
                <PMID Version="1">16514197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2006 Apr 25;249(1-2):78-83</RefSource>
                <PMID Version="1">16513253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 2006 Jun;74(6):1073-82</RefSource>
                <PMID Version="1">16436528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2006 Jun;91(6):2327-33</RefSource>
                <PMID Version="1">16551732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2006 Jul;16(7):485-95</RefSource>
                <PMID Version="1">16788381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 2006 Jul;21(7):1705-19</RefSource>
                <PMID Version="1">16571642</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Reprod Biol Endocrinol. 2006;4:20</RefSource>
                <PMID Version="1">16611365</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 2006 Aug;21(8):2189-93</RefSource>
                <PMID Version="1">16684841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2006 Aug;91(8):2920-5</RefSource>
                <PMID Version="1">16720653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2006 Oct;86(4):1009-12</RefSource>
                <PMID Version="1">17027369</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 2006 Dec;75(6):836-43</RefSource>
                <PMID Version="1">16943361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2007 Jan;87(1):143-6</RefSource>
                <PMID Version="1">17156781</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2007 Feb;92(2):705-13</RefSource>
                <PMID Version="1">17148555</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2008 Mar;149(3):1026-30</RefSource>
                <PMID Version="1">18063682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod Update. 2008 Mar-Apr;14(2):159-77</RefSource>
                <PMID Version="1">18175787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 2008 May;89(5 Suppl):1430-40</RefSource>
                <PMID Version="1">17624341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Reprod. 2010 Feb;25(2):544-51</RefSource>
                <PMID Version="1">19910321</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055430">Bone Morphogenetic Protein 15</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D052006">Bone Morphogenetic Protein Receptors, Type II</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054885">Cumulus Cells</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005307">Fertilization in Vitro</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015571">Follicular Fluid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055429">Growth Differentiation Factor 9</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017588">Hyperandrogenism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009865">Oocytes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010062">Ovulation Induction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011085">Polycystic Ovary Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018873">Pregnancy Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011374">Progesterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059010">Single-Cell Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3492567</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10815-012-9825-8</ArticleId>
            <ArticleId IdType="pubmed">22825968</ArticleId>
            <ArticleId IdType="pmc">PMC3492567</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16855006</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1530-6860</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
                <ISOAbbreviation>FASEB J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1877-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides that bind to two receptors, CRF(1) and CRF(2). While CRF(1) is a high-affinity receptor for CRF, urocortin III binds with much greater affinity to CRF(2). In the present study we investigated the effect of CRF(2) receptor activation with urocortin III on airway smooth muscle tone in vitro and in an acute model of airway inflammation in mice. Urocortin III caused relaxation of methacholine-precontracted mouse tracheal segments. CRF caused similar relaxation, but with reduced potency compared to urocortin III, consistent with the CRF(2) receptor subtype. Relaxation induced by urocortin III was concentration-dependently inhibited by the CRF(2) antagonist, astressin 2B, with an IC(50) in the nanomolar range. These relaxations were potentiated by inhibition of phosphodiesterases but unaffected by inhibition of cyclooxygenase and NO or by removal of the epithelium. Finally, the number of neutrophils retrieved by bronchoalveolar lavage after administration of bacterial LPS (LPS) was reduced by prior intraperitoneal (i.p.) injection of urocortin III. This effect was also suppressed by astressin 2B, implicating CRF(2) receptors. Therefore, CRF(2) agonists appear to have both bronchorelaxant and anti-inflammatory activities and might represent an interesting therapeutic approach to the treatment of inflammatory lung diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moffatt</LastName>
                    <ForeName>James D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Sackler Institute of Pulmonary Pharmacology, King's College London, Guy's Campus, London, UK. james.moffatt@kcl.ac.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lever</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Page</LastName>
                    <ForeName>Clive P</ForeName>
                    <Initials>CP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>07</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>FASEB J</MedlineTA>
            <NlmUniqueID>8804484</NlmUniqueID>
            <ISSNLinking>0892-6638</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C101531">CRF receptor type 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018019">Receptors, Corticotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C120841">astressin B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9015-71-8</RegistryNumber>
                <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001993">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003346">Corticotropin-Releasing Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007537">Isometric Contraction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008171">Lung Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009130">Muscle, Smooth</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018019">Receptors, Corticotropin-Releasing Hormone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000819">agonists</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014132">Trachea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">fj.05-5315fje</ArticleId>
            <ArticleId IdType="doi">10.1096/fj.05-5315fje</ArticleId>
            <ArticleId IdType="pubmed">16855006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6444804</PMID>
        <DateCreated>
            <Year>1980</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1980</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9985</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>104</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1980</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of pathology &amp; laboratory medicine</Title>
                <ISOAbbreviation>Arch. Pathol. Lab. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fetal exposure to anticonvulsant drugs. Detailed pathological study of a case.</ArticleTitle>
            <Pagination>
                <MedlinePgn>215-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Autopsy findings are discussed of a 23-month-old child exposed in utero to anticonvulsant therapy. Major abnormalities were confined to the heart and brain. The former consisted of massive biventricular hypertrophy with chamber obliteration. Except for generalized cerebral gliosis, the abnormalities in the brain were confined to the cerebellum, where malformation of the dentate nuclei, neuronal heterotopias, and abnormalities of Purkinje's cell dendrites were found. These findings lend further evidence for anticonvulsant teratogenicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mallow</LastName>
                    <ForeName>D W</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herrick</LastName>
                    <ForeName>M K</ForeName>
                    <Initials>MK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gathman</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Pathol Lab Med</MedlineTA>
            <NlmUniqueID>7607091</NlmUniqueID>
            <ISSNLinking>0003-9985</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>13AFD7670Q</RegistryNumber>
                <NameOfSubstance UI="D011324">Primidone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5SEH9X1D1D</RegistryNumber>
                <NameOfSubstance UI="D005013">Ethosuximide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>O3FX965V0I</RegistryNumber>
                <NameOfSubstance UI="D000086">Acetazolamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000014">Abnormalities, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000086">Acetazolamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005013">Ethosuximide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006330">Heart Defects, Congenital</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008431">Maternal-Fetal Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011248">Pregnancy Complications</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011324">Primidone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011689">Purkinje Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1980</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1980</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1980</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6444804</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15964614</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-1281</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>107</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Acta histochemica</Title>
                <ISOAbbreviation>Acta Histochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective effects of a calcium channel blocker on apoptosis in thymus of neonatal STZ-diabetic rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>207-14</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Streptozotocin (STZ) is known to induce insulin-dependent diabetes in experimental animals. In STZ-induced diabetes, atrophy of the thymus is caused by elevated intracellular calcium levels leading to apoptosis. Hyperglycemia is known to result in a decrease in numbers of T cells in the thymus and circulation. Intracellular calcium levels increase in diabetic animals after induction by STZ. Hyperglycemia inhibits Ca2+-ATPase and increases intracellular calcium levels. We have investigated apoptosis in thymus tissue of neonatal STZ (n-STZ)-diabetic rats and the effects of isradipine as a calcium channel blocker (CCB) on apoptosis. Five groups of newborn Wistar rats were used. On the second day after birth, 100 mg/kg STZ was given i.p. to the first two groups. The first group was n-STZ diabetic. To the second group, starting from the 12th week, 5 mg/kg/day isradipine (i.p) was given for 6 weeks. To the third group, the same dose of isradipine was given on the second day, followed by STZ treatment. The fourth group was non-diabetic and treated with 5 mg/kg/day isradipine for six weeks. The fifth group consisted of non-diabetic rats. To the sixth group, dexamethasone (5 mg/kg i.p.) was given to adult rats. For detection of apoptotic cells in paraffin-embedded thymus sections, the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) assay was used. The DNA ladder method was performed for analysis of DNA fragmentation. In the isradipine-treated non-diabetic group, typical apoptotic banding patterns were found, whereas thick bands between 123 and 246 bp length were found in the n-STZ- and n-STZ+isradipine-treated groups. More apoptotic cells were observed in the thymus of isradipine-treated, n-STZ-treated and n-STZ+isradipine-treated groups when compared with the non-diabetic control and isradipine+n-STZ-treated groups. In conclusion, we observed that long-term STZ diabetes results in apoptosis in the thymus. We also found that isradipine administered before STZ has protective effects against apoptosis, whereas isradipine alone induces apoptosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kaya Dağistanli</LastName>
                    <ForeName>Fatma</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa 34303, Istanbul, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Süsleyici Duman</LastName>
                    <ForeName>Belgin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oztürk</LastName>
                    <ForeName>Melek</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Acta Histochem</MedlineTA>
            <NlmUniqueID>0370320</NlmUniqueID>
            <ISSNLinking>0065-1281</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7S5I7G3JQL</RegistryNumber>
                <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YO1UK1S598</RegistryNumber>
                <NameOfSubstance UI="D017275">Isradipine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000831">Animals, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002452">Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053938">DNA Fragmentation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003907">Dexamethasone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020287">In Situ Nick-End Labeling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017275">Isradipine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013950">Thymus Gland</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0065-1281(05)00032-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.acthis.2005.03.005</ArticleId>
            <ArticleId IdType="pubmed">15964614</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16507461</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>07</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6765</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>114</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>379-85</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The Cesare Maltoni Cancer Research Center of the European Ramazzini Foundation has conducted a long-term bioassay on aspartame (APM), a widely used artificial sweetener. APM was administered with feed to 8-week-old Sprague-Dawley rats (100-150/sex/group), at concentrations of 100,000, 50,000, 10,000, 2,000, 400, 80, or 0 ppm. The treatment lasted until natural death, at which time all deceased animals underwent complete necropsy. Histopathologic evaluation of all pathologic lesions and of all organs and tissues collected was routinely performed on each animal of all experimental groups. The results of the study show for the first time that APM, in our experimental conditions, causes a) an increased incidence of malignant-tumor-bearing animals with a positive significant trend in males (p &lt; or = 0.05) and in females (p &lt; or = 0.01), in particular those females treated at 50,000 ppm (p &lt; or = 0.01); b) an increase in lymphomas and leukemias with a positive significant trend in both males (p &lt; or = 0.05) and females (p &lt; or = 0.01), in particular in females treated at doses of 100,000 (p &lt; or = 0.01), 50,000 (p &lt; or = 0.01), 10,000 (p &lt; or = 0.05), 2,000 (p &lt; or = 0.05), or 400 ppm (p &lt; or = 0.01); c) a statistically significant increased incidence, with a positive significant trend (p &lt; or = 0.01), of transitional cell carcinomas of the renal pelvis and ureter and their precursors (dysplasias) in females treated at 100,000 (p &lt; or = 0.01), 50,000 (p &lt; or = 0.01), 10,000 (p &lt; or = 0.01), 2,000 (p &lt; or = 0.05), or 400 ppm (p &lt; or = 0.05); and d) an increased incidence of malignant schwannomas of peripheral nerves with a positive trend (p &lt; or = 0.05) in males. The results of this mega-experiment indicate that APM is a multipotential carcinogenic agent, even at a daily dose of 20 mg/kg body weight, much less than the current acceptable daily intake. On the basis of these results, a reevaluation of the present guidelines on the use and consumption of APM is urgent and cannot be delayed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Soffritti</LastName>
                    <ForeName>Morando</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cesare Maltoni Cancer Research Center, European Ramazzini Foundation of Oncology and Environmental Sciences, Bologna, Italy. crcfr@ramazzini.it</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belpoggi</LastName>
                    <ForeName>Fiorella</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Degli Esposti</LastName>
                    <ForeName>Davide</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lambertini</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tibaldi</LastName>
                    <ForeName>Eva</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rigano</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013549">Sweetening Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Z0H242BBR1</RegistryNumber>
                <NameOfSubstance UI="D001218">Aspartame</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2002 Dec;982:26-45</RefSource>
                <PMID Version="1">12562627</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Pathol. 1996 Sep-Oct;24(5):573-9</RefSource>
                <PMID Version="1">8923678</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2002 Dec;982:87-105</RefSource>
                <PMID Version="1">12562630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Environ Health. 1976 Nov;2(2):441-51</RefSource>
                <PMID Version="1">827618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 1979 Apr;62(4):957-74</RefSource>
                <PMID Version="1">285297</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 1981 Mar;7(6):433-7</RefSource>
                <PMID Version="1">7245229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 1981;21(2):91-4</RefSource>
                <PMID Version="1">7281205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biometrics. 1988 Jun;44(2):417-31</RefSource>
                <PMID Version="1">3390507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1989 May;12(4):731-7</RefSource>
                <PMID Version="1">2744275</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1989 Jul;82:109-24</RefSource>
                <PMID Version="1">2792037</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Ind Health. 1989 Oct;5(5):699-730</RefSource>
                <PMID Version="1">2815102</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Jpn J Cancer Res. 1989 Sep;80(9):795-807</RefSource>
                <PMID Version="1">2513295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>IARC Sci Publ. 1993;(122 Pt I-4):1-27</RefSource>
                <PMID Version="1">8270318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2002 Dec;982:46-69</RefSource>
                <PMID Version="1">12562628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1995 Sep;103 Suppl 6:173-5</RefSource>
                <PMID Version="1">8549469</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Ind Health. 1995 Mar-Apr;11(2):119-49</RefSource>
                <PMID Version="1">7491630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World Rev Nutr Diet. 1999;85:201-11</RefSource>
                <PMID Version="1">10647352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 1999;895:34-55</RefSource>
                <PMID Version="1">10676408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 1999;895:56-79</RefSource>
                <PMID Version="1">10676409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Food Chem Toxicol. 2000 Jan;38(1):75-7</RefSource>
                <PMID Version="1">10685017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Food Chem Toxicol. 2000 Apr;38(4):335-8</RefSource>
                <PMID Version="1">10722887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Environ Health Perspect. 2007 Jan;115(1):A16-7; author reply A17</RefSource>
                <PMID Version="1">17366802</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Environ Health Perspect. 2006 Sep;114(9):A516; author reply A516-7</RefSource>
                <PMID Version="1">16966071</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Environ Health Perspect. 2006 Mar;114(3):A176</RefSource>
                <PMID Version="1">16528837</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001218">Aspartame</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002277">Carcinoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007680">Kidney Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007938">Leukemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008223">Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013549">Sweetening Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014516">Ureteral Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1392232</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16507461</ArticleId>
            <ArticleId IdType="pmc">PMC1392232</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16507464</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>07</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6765</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>114</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>404-11</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Our previous work has shown that exposure to inorganic arsenic in utero produces hepatocellular carcinoma (HCC) in adult male mice. To explore further the molecular mechanisms of transplacental arsenic hepatocarcinogenesis, we conducted a second arsenic transplacental carcinogenesis study and used a genomewide microarray to profile arsenic-induced aberrant gene expression more extensively. Briefly, pregnant C3H mice were given drinking water containing 85 ppm arsenic as sodium arsenite or unaltered water from days 8 to 18 of gestation. The incidence of HCC in adult male offspring was increased 4-fold and tumor multiplicity 3-fold after transplacental arsenic exposure. Samples of normal liver and liver tumors were taken at autopsy for genomic analysis. Arsenic exposure in utero resulted in significant alterations (p &lt; 0.001) in the expression of 2,010 genes in arsenic-exposed liver samples and in the expression of 2,540 genes in arsenic-induced HCC. Ingenuity Pathway Analysis revealed that significant alterations in gene expression occurred in a number of biological networks, and Myc plays a critical role in one of the primary networks. Real-time reverse transcriptase-polymerase chain reaction and Western blot analysis of selected genes/proteins showed &gt; 90% concordance. Arsenic-altered gene expression included activation of oncogenes and HCC biomarkers, and increased expression of cell proliferation-related genes, stress proteins, and insulin-like growth factors and genes involved in cell-cell communications. Liver feminization was evidenced by increased expression of estrogen-linked genes and altered expression of genes that encode gender-related metabolic enzymes. These novel findings are in agreement with the biology and histology of arsenic-induced HCC, thereby indicating that multiple genetic events are associated with transplacental arsenic hepatocarcinogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Yaxiong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ducharme</LastName>
                    <ForeName>Danica M K</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diwan</LastName>
                    <ForeName>Bhalchandra A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merrick</LastName>
                    <ForeName>B Alex</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grissom</LastName>
                    <ForeName>Sherry F</ForeName>
                    <Initials>SF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tucker</LastName>
                    <ForeName>Charles J</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paules</LastName>
                    <ForeName>Richard S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tennant</LastName>
                    <ForeName>Raymond</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waalkes</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>N01-CO-12400</GrantID>
                    <Acronym>CO</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>N712M78A8G</RegistryNumber>
                <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Carcinog. 2001 Feb;30(2):79-87</RefSource>
                <PMID Version="1">11241755</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98</RefSource>
                <PMID Version="1">16039940</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2001 Jun;61(2):314-20</RefSource>
                <PMID Version="1">11353140</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2001 Mar-Apr;21(2B):1339-45</RefSource>
                <PMID Version="1">11396210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2000 Apr 15;164(2):161-70</RefSource>
                <PMID Version="1">10764629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2000 Jun;55(2):460-7</RefSource>
                <PMID Version="1">10828279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94</RefSource>
                <PMID Version="1">10852857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2000 Jul 1;60(13):3445-53</RefSource>
                <PMID Version="1">10910055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Jul;108(7):655-61</RefSource>
                <PMID Version="1">10903620</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Clin Toxicol. 2000;38(4):395-405</RefSource>
                <PMID Version="1">10930056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2001 Jan;59(1):185-92</RefSource>
                <PMID Version="1">11134558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Jul 15;61(14):5389-95</RefSource>
                <PMID Version="1">11454681</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2001 Aug;60(2):302-9</RefSource>
                <PMID Version="1">11455017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8</RefSource>
                <PMID Version="1">11559025</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71</RefSource>
                <PMID Version="1">11578149</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2002 Feb;110(2):119-22</RefSource>
                <PMID Version="1">11836136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 2002 Mar 10;128(1-3):73-84</RefSource>
                <PMID Version="1">11869819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2002 May;23(5):777-85</RefSource>
                <PMID Version="1">12016150</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cancer. 2002 Jun 10;99(5):629-34</RefSource>
                <PMID Version="1">12115494</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2002 Aug;23(8):1387-97</RefSource>
                <PMID Version="1">12151359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Alcohol. 2002 Jul;27(3):155-62</RefSource>
                <PMID Version="1">12163143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2002 Oct;110 Suppl 5:883-6</RefSource>
                <PMID Version="1">12426152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17</RefSource>
                <PMID Version="1">12583988</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2003 Apr;24(4):757-70</RefSource>
                <PMID Version="1">12727805</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Cell Res. 2003 Nov 1;290(2):234-45</RefSource>
                <PMID Version="1">14567983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2004 Jan;25(1):133-41</RefSource>
                <PMID Version="1">14514661</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Metab Res. 2003 Nov-Dec;35(11-12):685-93</RefSource>
                <PMID Version="1">14710347</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Pathol. 2004 Jan-Feb;32(1):64-72</RefSource>
                <PMID Version="1">14713550</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2004 Feb;77(2):249-57</RefSource>
                <PMID Version="1">14691202</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2004 Mar 17;96(6):466-74</RefSource>
                <PMID Version="1">15026472</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Public Health. 2004 May;94(5):741-4</RefSource>
                <PMID Version="1">15117692</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Jul 30;279(31):32700-8</RefSource>
                <PMID Version="1">15161912</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2004 Sep;25(9):1779-86</RefSource>
                <PMID Version="1">15073043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lab Invest. 2004 Sep;84(9):1137-47</RefSource>
                <PMID Version="1">15220935</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Aug;112(12):1255-63</RefSource>
                <PMID Version="1">15345372</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Environ Health A. 2004 Oct 8;67(19):1491-500</RefSource>
                <PMID Version="1">15371225</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440</RefSource>
                <PMID Version="1">3482203</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hyg Epidemiol Microbiol Immunol. 1988;32(2):137-46</RefSource>
                <PMID Version="1">2457611</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1996 May;277(2):1026-33</RefSource>
                <PMID Version="1">8627513</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gastroenterol Hepatol. 1997 Oct;12(9-10):S294-308</RefSource>
                <PMID Version="1">9407350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 1998 Aug;18(8):4499-508</RefSource>
                <PMID Version="1">9671459</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 1998 Aug;44(2):185-90</RefSource>
                <PMID Version="1">9742656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 1998 Dec;153(6):1775-85</RefSource>
                <PMID Version="1">9846968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Gastroenterol. 2004 Dec 1;10(23):3414-8</RefSource>
                <PMID Version="1">15526358</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Oncol. 2005 Feb;26(2):369-77</RefSource>
                <PMID Version="1">15645121</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS J. 2005 Jan;272(2):413-21</RefSource>
                <PMID Version="1">15654879</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2005 Mar 10;24(11):1831-46</RefSource>
                <PMID Version="1">15674350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9</RefSource>
                <PMID Version="1">15937110</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61</RefSource>
                <PMID Version="1">11312654</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001151">Arsenic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006528">Carcinoma, Hepatocellular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008431">Maternal-Fetal Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043922">Toxicogenetics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1392235</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16507464</ArticleId>
            <ArticleId IdType="pmc">PMC1392235</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3573184</PMID>
        <DateCreated>
            <Year>1987</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1987</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-5347</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>137</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1987</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of urology</Title>
                <ISOAbbreviation>J. Urol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical significance of hematuria in patients on anticoagulant therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>923-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We evaluated 29 consecutive patients in whom gross or microscopic hematuria developed while they were on heparin or warfarin anticoagulant therapy. Patients who had bleeding as a result of anticoagulant overdosage and/or from an additional organ system(s) other than the urinary tract were excluded from this review. Significant pathological findings consisting of carcinoma, calculi, renal infarction, infection, benign prostatic hyperplasia and/or adult polycystic renal disease were identified in 17 patients. Insignificant or incidental pathological findings classified as posterior urethritis, simple renal cyst or renal scarring were noted in 6 patients. No pathological condition was found in the remaining 6 patients. We conclude that a thorough and appropriate evaluation of the urinary tract should be conducted in patients on anticoagulant therapy who have gross or microscopic hematuria, since a pathological lesion of variable clinical significance often is discovered.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schuster</LastName>
                    <ForeName>G A</ForeName>
                    <Initials>GA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lewis</LastName>
                    <ForeName>G A</ForeName>
                    <Initials>GA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Urol</MedlineTA>
            <NlmUniqueID>0376374</NlmUniqueID>
            <ISSNLinking>0022-5347</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
                <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9005-49-6</RegistryNumber>
                <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006417">Hematuria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006493">Heparin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014545">Urinary Calculi</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014571">Urologic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014859">Warfarin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1987</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3573184</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17425932</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>04</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1603-6824</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>169</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Mar</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Ugeskrift for laeger</Title>
                <ISOAbbreviation>Ugeskr. Laeg.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Losartan-induced Stevens-Johnson syndrome in a geriatric patient].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1233-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Stevens-Johnson syndrome is an acute inflammatory and reactive disorder with skin and severe mucous membrane changes. Often patients have associated constitutional symptoms, including fever. The syndrome can be precipitated by infection or medication. We report a case of losartan-induced Stevens-Johnson syndrome associated with renal impairment in a geriatric patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bonnici</LastName>
                    <ForeName>Hanne</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Odense Universitetshospital, Geriatrisk Afdeling G. hannebonnici@hotmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bygum</LastName>
                    <ForeName>Anette</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>dan</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Losartanudløst Stevens-Johnsons syndrom hos en geriatrisk patient.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Ugeskr Laeger</MedlineTA>
            <NlmUniqueID>0141730</NlmUniqueID>
            <ISSNLinking>0041-5782</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JMS50MPO89</RegistryNumber>
                <NameOfSubstance UI="D019808">Losartan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047228">Angiotensin II Type 1 Receptor Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019808">Losartan</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013262">Stevens-Johnson Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">VP48419</ArticleId>
            <ArticleId IdType="pubmed">17425932</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2559225</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>03</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>03</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-5198</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>51</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Japanese journal of pharmacology</Title>
                <ISOAbbreviation>Jpn. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of KT-362, a new Na and Ca influx and Ca release inhibitor, on canine ventricular arrhythmias.</ArticleTitle>
            <Pagination>
                <MedlinePgn>475-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Antiarrhythmic effects of the new drug KT-362, which was reported to suppress Na and Ca currents of cardiac cells and also to suppress intracellular Ca release in isolated smooth muscle preparations, were examined using two-stage coronary ligation-, digitalis- and adrenaline-induced ventricular arrhythmias in the dog. Intravenous KT-362 at 10 mg/kg suppressed coronary ligation arrhythmia both at 24 and 48 hr after ligation, and the minimum effective plasma concentrations for arrhythmias induced by 24 hr coronary ligation and 48 hr coronary ligation were 6.1 +/- 1.7 and 8.6 +/- 2.7 micrograms/ml, respectively. Antiarrhythmic effects were accompanied by transient hypotension. Oral administration of 70-100 mg/kg was also effective on 24 hr coronary ligation arrhythmia. However, there was no prominent hypotension in these experiments. Intravenous KT-362 at 3 mg/kg suppressed digitalis arrhythmia; and the minimum effective plasma concentration was 3.3 +/- 1.2 micrograms/ml, which was lower than the effective plasma concentrations for coronary ligation arrhythmias. Intravenous KT-362 at 1 mg/kg also suppressed adrenaline arrhythmia; and the minimum effective plasma concentration was 1.0 +/- 0.1 microgram/ml, the lowest among the effective plasma concentrations. These pharmacological profiles of KT-362 are quite different from those of class 4 Ca antagonists, but similar to those of class 1 drugs such as propafenone. Though KT-362 has a hypotensive effect, it is effective on canine ventricular arrhythmias; thus its clinical usefulness for supraventricular and ventricular arrhythmias is expected.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hashimoto</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Yamanashi Medical College, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mochizuki</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomiyama</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Jpn J Pharmacol</MedlineTA>
            <NlmUniqueID>2983305R</NlmUniqueID>
            <ISSNLinking>0021-5198</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013841">Thiazepines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>105394-80-7</RegistryNumber>
                <NameOfSubstance UI="C051271">KT 362</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YKH834O4BH</RegistryNumber>
                <NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001145">Arrhythmias, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003331">Coronary Vessels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004070">Digitalis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004837">Epinephrine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010946">Plants, Medicinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010947">Plants, Toxic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015222">Sodium Channels</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013841">Thiazepines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2559225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19761151</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0970-258X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <MedlineDate>2009 Jan-Feb</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>The National medical journal of India</Title>
                <ISOAbbreviation>Natl Med J India</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of puerarin on the expression of extracellular matrix in rats with streptozotocin-induced diabetic nephropathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-12</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inhibition of the formation of advanced glycation end-products delays the development of diabetic nephropathy. Puerarin decreases the formation of these products. We studied the effect of puerarin in a rat model of diabetic nephropathy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Three groups of rats were studied: a control group, a diabetic group in whom diabetic nephropathy was induced by intraperitoneal injection of streptozotocin, and a puerarin group in which diabetic rats were treated with puerarin. During and after treatment, measurements were made on the rats' general status, blood glucose level, blood urea nitrogen, serum creatinine, creatinine clearance rate and urinary albumin excretion over 24 hours. The expression of collagen I and heparan sulphate proteoglycan in the extracellular matrix of the glomerulus was assessed by immunohistochemistry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Rats in the puerarin group had a better general condition than those with diabetes. They also had lower blood urea nitrogen, serum creatinine and urinary albumin excretion rate over 24 hours compared with those in the diabetic group. The creatinine clearance and expression of heparan sulphate proteoglycan in the kidney also increased significantly in the puerarin group compared with that in the diabetic group.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Puerarin seems to have certain protective effects on diabetic nephropathy induced by streptozotocin. This is caused possibly by regulating the expression of glomerular extracellular matrix.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Qiangxiang</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Xiangya Hospital, Central South University, Changsha 410008, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Hanren</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Daojun</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Feiyue</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Qun</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Huiling</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhong</LastName>
                    <ForeName>Huiju</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Natl Med J India</MedlineTA>
            <NlmUniqueID>8809315</NlmUniqueID>
            <ISSNLinking>0970-258X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006442">Hemoglobin A, Glycosylated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Z9W8997416</RegistryNumber>
                <NameOfSubstance UI="C033607">puerarin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005109">Extracellular Matrix</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050533">Glomerular Basement Membrane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006442">Hemoglobin A, Glycosylated</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007529">Isoflavones</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023421">Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014665">Vasodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19761151</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6429213</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>07</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>07</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0271-0749</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1984</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical psychopharmacology</Title>
                <ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Imipramine-induced inappropriate ADH secretion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This case demonstrates the occurrence of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in association with the administration of several antidepressant medications. The SIADH was shown by rechallenge to be associated with imipramine, an antidepressant not previously associated with SIADH. In addition, SIADH appeared to occur with bupropion, a new antidepressant structurally dissimilar to tricyclic antidepressants.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liskin</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walsh</LastName>
                    <ForeName>B T</ForeName>
                    <Initials>BT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roose</LastName>
                    <ForeName>S P</ForeName>
                    <Initials>SP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Clin Psychopharmacol</MedlineTA>
            <NlmUniqueID>8109496</NlmUniqueID>
            <ISSNLinking>0271-0749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011427">Propiophenones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>01ZG3TPX31</RegistryNumber>
                <NameOfSubstance UI="D016642">Bupropion</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>OGG85SX4E4</RegistryNumber>
                <NameOfSubstance UI="D007099">Imipramine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016642">Bupropion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007010">Hyponatremia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007099">Imipramine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007177">Inappropriate ADH Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011427">Propiophenones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6429213</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19560849</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-6838</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of kidney diseases : the official journal of the National Kidney Foundation</Title>
                <ISOAbbreviation>Am. J. Kidney Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cinacalcet-induced leukocytoclastic vasculitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e5-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.ajkd.2009.02.019</ELocationID>
            <Abstract>
                <AbstractText>An 80-year-old woman on maintenance hemodialysis therapy developed severe hypercalcemia under vitamin D treatment for secondary hyperparathyroidism. To avoid the toxic calcemic effects, cinacalcet was introduced and the dose of vitamin D was substantially decreased. Cinacalcet targets the calcium-sensing receptor and decreases parathyroid hormone levels without increasing calcium and phosphorus levels. Three days after starting cinacalcet therapy, the patient developed palpable purpura on both upper and lower extremities that resolved after discontinuation of cinacalcet and administration of steroids. Skin biopsy of the initial eruption showed leukocytoclastic vasculitis. According to the Naranjo adverse drug reaction probability scale, leukocytoclastic vasculitis probably was caused by cinacalcet introduction. Drug-induced vasculitis is a poorly defined disorder, and, in most cases, no pathogenetic mechanism can be described. An idiosyncratic reaction to the agent often is proposed. Cinacalcet should be considered a causative agent of cutaneous leukocytoclastic vasculitis, and although this is the result of only a clinical observation, further attention is required in the future because cinacalcet recently has been introduced in the treatment of secondary hyperparathyroidism in patients on long-term hemodialysis therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Giannikopoulos</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, General Hospital of Chios, Chios, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zorzou</LastName>
                    <ForeName>Markela-Pagonitsa</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stamoulis</LastName>
                    <ForeName>Ioannis</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Panagi</LastName>
                    <ForeName>Georgia</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sitaras</LastName>
                    <ForeName>Panagiotis</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Georgopoulos</LastName>
                    <ForeName>Ioannis</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hadjileontis</LastName>
                    <ForeName>Constantinos</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malakos</LastName>
                    <ForeName>Ioannis</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kyriazis</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Kidney Dis</MedlineTA>
            <NlmUniqueID>8110075</NlmUniqueID>
            <ISSNLinking>0272-6386</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UAZ6V7728S</RegistryNumber>
                <NameOfSubstance UI="C476217">cinacalcet</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009281">Naphthalenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018366">Vasculitis, Leukocytoclastic, Cutaneous</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0272-6386(09)00721-5</ArticleId>
            <ArticleId IdType="doi">10.1053/j.ajkd.2009.02.019</ArticleId>
            <ArticleId IdType="pubmed">19560849</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15964507</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0891-5849</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>39</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jul</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Free radical biology &amp; medicine</Title>
                <ISOAbbreviation>Free Radic. Biol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenomic profiling of an oxidative stress-mediated spongiform encephalopathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>152-63</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The majority of cellular superoxide is generated in the mitochondria as a by-product of normal oxidative metabolism. In the mitochondria, superoxide is detoxified by manganese superoxide dismutase (SOD2). Mice lacking SOD2 demonstrate a multifaceted neonatal lethal phenotype, including a spongiform encephalopathy that is preventable through antioxidant treatment. The molecular events behind the observed pathology in the cortex of these mice are unknown. We hypothesized that the lack of SOD2 would result in significant changes in cortical gene expression and that therapeutically beneficial antioxidant treatment would normalize the expression of some genes, providing insight into the mechanism by which mitochondrial oxidative stress results in neurodegeneration. We report the identification of gene expression profiles associated with this paradigm, which characterize the degree of response to the pharmacologic intervention. We have identified specific pathways targeted by endogenous oxidative stress, including glutathione metabolism, iron metabolism, and cell-survival pathways centering on the kinase AKT. The normalization of expression of some of these pathways by antioxidant treatment suggests approaches to treating disease in which endogenous oxidative stress plays a role.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Golden</LastName>
                    <ForeName>Tamara R</ForeName>
                    <Initials>TR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hubbard</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morten</LastName>
                    <ForeName>Karl J</ForeName>
                    <Initials>KJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hinerfeld</LastName>
                    <ForeName>Doug</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melov</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AG18679</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Free Radic Biol Med</MedlineTA>
            <NlmUniqueID>8709159</NlmUniqueID>
            <ISSNLinking>0891-5849</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E1UOL152H7</RegistryNumber>
                <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="C431683">superoxide dismutase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.3.1.2</RegistryNumber>
                <NameOfSubstance UI="D005974">Glutamate-Ammonia Ligase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GAN16C9B8O</RegistryNumber>
                <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016000">Cluster Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018076">DNA, Complementary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016166">Free Radical Scavengers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005974">Glutamate-Ammonia Ligase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007501">Iron</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019636">Neurodegenerative Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010597">Pharmacogenetics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017096">Prion Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0891-5849(05)00129-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.03.002</ArticleId>
            <ArticleId IdType="pubmed">15964507</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3862460</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1188</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>85</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of pharmacology</Title>
                <ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modification of dyskinesias following the intrastriatal injection of prostaglandins in the rodent.</ArticleTitle>
            <Pagination>
                <MedlinePgn>943-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The abilities of prostaglandin E1 (PGE1), PGE2, PGD2 and PGF2 alpha to antagonize striatal dopamine function were assessed following bilateral and unilateral injections into the striata of the rat and guinea-pig. Three tests were used to assess the effects of the bilateral injections, ability to antagonize dyskinetic biting induced by 2-di-n-propylamino-5,6-dihydroxytetralin (0.025 mg kg-1 s.c.), ability to antagonize stereotyped behaviour induced by apomorphine (0.5 or 2 mg kg-1 s.c.) and ability to induce catalepsy. Asymmetry/circling behaviour revealed on challenge with apomorphine (0.25 mg kg-1 s.c.) was measured following unilateral injection into the striatum. In the rat, dyskinetic biting induced by 2-di-n-propylamino-5,6-dihydroxytetralin was antagonized by PGE1 (0.001-1 micrograms) and PGE2 (0.00001-1 micrograms) but not by PGD2 or PGF2 alpha (1 microgram). Stereotyped behaviour induced by apomorphine was not antagonized by any of the prostaglandins. A weak catalepsy was induced by PGE1 (1 microgram only), PGE2 (0.001-1 micrograms) and PGD2 (0.001-1 micrograms) but not by PGF2 alpha. Asymmetry and circling behaviour was only observed following the unilateral injection into the striatum of PGE1 and PGD2 (0.01-1 microgram) and challenge with apomorphine. In the guinea-pig the actions of PGE1 and E2 were compared with those of PGF2 alpha. Dyskinetic biting induced by 2-di-n-propylamino-5,6-dihydroxytetralin was antagonized by bilateral injections into the striatum of PGE2 (0.001-1 microgram), but not PGE1 (0.5 micrograms) and PGF2 alpha (1 microgram) but not PGE, (0.5 micrograms) and PGF2 alpha (1 microgram). Similar injections of PGE1, E2 and F2 alpha, all failed to antagonize apomorphine-induced stereotyped behaviour, or to induce catalepsy. PGE, (0.01-0.5 fig) and PGE2 (0.002-1 pg), but not PGF2 alpha, caused asymmetry following unilateral injection into the striatum and peripheral challenge with apomorphine. 5 It is concluded that the major effect in the striatum of the prostaglandins of the E series is to antagonize dyskinetic biting; this action is not shared by other prostaglandins tested, and does not reflect a generalised ability to antagonize striatal dopamine function. It is suggested that the actions of the prostaglandins to modify differentially dopamine-dependent behaviours from the striatum may reflect activity at a site subsequent to the dopamine receptor.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Costall</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holmes</LastName>
                    <ForeName>S W</ForeName>
                    <Initials>SW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly</LastName>
                    <ForeName>M E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naylor</LastName>
                    <ForeName>R J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Pharmacol</MedlineTA>
            <NlmUniqueID>7502536</NlmUniqueID>
            <ISSNLinking>0007-1188</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011457">Prostaglandins D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011458">Prostaglandins E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011460">Prostaglandins F</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>64309-39-3</RegistryNumber>
                <NameOfSubstance UI="C015842">2-(N,N-dipropyl)amino-5,6-dihydroxytetralin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B7IN85G1HY</RegistryNumber>
                <NameOfSubstance UI="D015237">Dinoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>F5TD010360</RegistryNumber>
                <NameOfSubstance UI="D000527">Alprostadil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K7Q1JQR04M</RegistryNumber>
                <NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N21FAR7B4S</RegistryNumber>
                <NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RXY07S6CZ2</RegistryNumber>
                <NameOfSubstance UI="D015230">Prostaglandin D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VTD58H1Z2X</RegistryNumber>
                <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 1972 Sep;11(5):645-63</RefSource>
                <PMID Version="1">4597256</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 1975 Apr;18(4):362-7</RefSource>
                <PMID Version="1">1168259</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Physiol. 1979;41:669-84</RefSource>
                <PMID Version="1">35094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1979 Sep;237(3):H381-5</RefSource>
                <PMID Version="1">382872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1980 Jun 27;64(4):349-55</RefSource>
                <PMID Version="1">7389827</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 1980 Jul;19(7):623-31</RefSource>
                <PMID Version="1">7190654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pol J Pharmacol Pharm. 1980 Sep-Oct;32(5):639-41</RefSource>
                <PMID Version="1">6267565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Biochem Behav. 1982 Dec;17(6):1233-7</RefSource>
                <PMID Version="1">6819586</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pol J Pharmacol Pharm. 1982;34(1-3):147-52</RefSource>
                <PMID Version="1">7167415</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Med Bull. 1983 Jul;39(3):265-70</RefSource>
                <PMID Version="1">6414573</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1983 Dec 9;96(1-2):79-86</RefSource>
                <PMID Version="1">6141060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biomed Biochim Acta. 1983;42(9):1211-4</RefSource>
                <PMID Version="1">6367735</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 1984 Nov;83(3):733-40</RefSource>
                <PMID Version="1">6542444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol Chemother. 1964 Feb;22:189-92</RefSource>
                <PMID Version="1">14126050</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000527">Alprostadil</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015237">Dinoprost</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007839">Functional Laterality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006168">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015230">Prostaglandin D2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011457">Prostaglandins D</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011458">Prostaglandins E</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011460">Prostaglandins F</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013239">Stereotyped Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013764">Tetrahydronaphthalenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1916651</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3862460</ArticleId>
            <ArticleId IdType="pmc">PMC1916651</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2334953</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-6569</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Catheterization and cardiovascular diagnosis</Title>
                <ISOAbbreviation>Cathet Cardiovasc Diagn</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.</ArticleTitle>
            <Pagination>
                <MedlinePgn>229-36</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Intracoronary papaverine commonly produces striking QT interval prolongation with rare but serious ventricular dysrhythmias reported. Because of 3 cases of severe papaverine-induced dysrhythmia in our laboratory, QT intervals and hemodynamic and intracoronary velocity data collected during intracoronary papaverine administration were retrospectively reviewed in 34 patients; 20 patients with angiographically normal coronary arteries (group 1) and 14 patients (group 2) before and (group 2) after single-vessel left coronary angioplasty. QT intervals increased from 394 +/- 44 to 464 +/- 73 msec, 414 +/- 47 to 504 +/- 95 msec, and 410 +/- 41 to 486 +/- 75 msec for groups 1 and 2 before and after angioplasty, respectively (all P less than 0.01). There was no correlation with hemodynamic, electrocardiographic, or coronary vasodilatory reserve responses and change in QTc interval. In the 3 index patients having significant papaverine-related arrhythmias, a baseline QT interval was prolonged (after prior papaverine exposure) in only 1 in association with torsade de pointes. These data indicate that QT interval prolongation after papaverine is a common occurrence, but that the production of ventricular dysrhythmia is probably idiosynchratic in origin. In view of these findings, we recommend that appropriate antiarrhythmic preparations be in place for patients receiving intracoronary papaverine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kern</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiology Division, St. Louis University Hospital, MO.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deligonul</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serota</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudipati</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buckingham</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Cathet Cardiovasc Diagn</MedlineTA>
            <NlmUniqueID>7508512</NlmUniqueID>
            <ISSNLinking>0098-6569</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>DAA13NKG2Q</RegistryNumber>
                <NameOfSubstance UI="D010208">Papaverine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001145">Arrhythmias, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001783">Blood Flow Velocity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003331">Coronary Vessels</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007269">Injections, Intra-Arterial</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008133">Long QT Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010208">Papaverine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014664">Vasodilation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2334953</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15146389</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>05</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>07</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0002-9297</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>75</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of human genetics</Title>
                <ISOAbbreviation>Am. J. Hum. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A HOX gene mutation in a family with isolated congenital vertical talus and Charcot-Marie-Tooth disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>92-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Congenital vertical talus (CVT), also known as &quot;rocker-bottom foot&quot; deformity, is a dislocation of the talonavicular joint, with rigid dorsal dislocation of the navicular over the neck of the talus. This condition is usually associated with multiple other congenital deformities and only rarely is an isolated deformity. The reported familial cases are consistent with an autosomal dominant mode of inheritance with incomplete penetrance. In contrast, Charcot-Marie-Tooth disease (CMT) is thought to be a completely distinct heterogeneous group of disorders, with foot abnormalities that typically develop a high-arched &quot;claw foot&quot; appearance later in life. In the present study, DNA was isolated from 36 members of a single upstate (northern) New York white family of Italian descent in which both CVT and CMT were segregating. Whole-genome linkage analysis with Affymetrix GeneChip Mapping 10K Array defined a 7-Mb critical region on chromosome 2q31, which led to candidate-gene sequencing of six HOX genes and detection of a single missense mutation, M319K (956T--&gt;A), in the HOXD10 gene. In the study family, this mutation was fully penetrant and exhibited significant evidence of linkage (LOD 6.33; theta =0), and it very likely accounts for both CVT and CMT in heterozygotes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shrimpton</LastName>
                    <ForeName>Antony E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, State University of New York, Upstate Medical University, Syracuse, 13210, USA. shrimpta@upstate.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levinsohn</LastName>
                    <ForeName>E Mark</ForeName>
                    <Initials>EM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yozawitz</LastName>
                    <ForeName>Justin M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Packard</LastName>
                    <ForeName>David S</ForeName>
                    <Initials>DS</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cady</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Middleton</LastName>
                    <ForeName>Frank A</ForeName>
                    <Initials>FA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Persico</LastName>
                    <ForeName>Antonio M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hootnick</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>05</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Hum Genet</MedlineTA>
            <NlmUniqueID>0370475</NlmUniqueID>
            <ISSNLinking>0002-9297</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C099223">hoxd10a protein, zebrafish</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>145420-66-2</RegistryNumber>
                <NameOfSubstance UI="C072064">HOXD10 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 2001 Jan;59(1):1-11</RefSource>
                <PMID Version="1">11206481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2002 Jan;30(1):97-101</RefSource>
                <PMID Version="1">11731797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2002 Feb;70(2):547-55</RefSource>
                <PMID Version="1">11778160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2002 May;19(5):573-4</RefSource>
                <PMID Version="1">11968094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Aug 1;418(6897):492-3</RefSource>
                <PMID Version="1">12152063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Iowa Orthop J. 2002;22:25-7</RefSource>
                <PMID Version="1">12180606</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet. 2002 Oct 15;112(3):256-65</RefSource>
                <PMID Version="1">12357469</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Nov 14;420(6912):145-50</RefSource>
                <PMID Version="1">12432383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2003 Oct;21(10):1233-7</RefSource>
                <PMID Version="1">12960966</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Orthop Relat Res. 1979 Mar-Apr;(139):128-32</RefSource>
                <PMID Version="1">455829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr Orthop. 1984 May;4(3):318-26</RefSource>
                <PMID Version="1">6736236</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 1989 Dec;36(6):427-30</RefSource>
                <PMID Version="1">2591068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1991 Jan 25;251(4992):426-30</RefSource>
                <PMID Version="1">1671176</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1994 Jul 29;78(2):191-201</RefSource>
                <PMID Version="1">7913880</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1994 Aug 9;33(31):9187-94</RefSource>
                <PMID Version="1">8049221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 1994 Aug 1;13(15):3551-60</RefSource>
                <PMID Version="1">7914870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Biochem. 1994;63:487-526</RefSource>
                <PMID Version="1">7979246</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1996 Apr 26;272(5261):548-51</RefSource>
                <PMID Version="1">8614804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 1996 May;122(5):1449-66</RefSource>
                <PMID Version="1">8625833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 1997 Feb;15(2):179-80</RefSource>
                <PMID Version="1">9020844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Muscle Nerve. 1999 Nov;22(11):1498-509</RefSource>
                <PMID Version="1">10514227</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002607">Charcot-Marie-Tooth Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002889">Chromosomes, Human, Pair 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005532">Foot Deformities, Congenital</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005799">Genes, Dominant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008040">Genetic Linkage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006579">Heterozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020125">Mutation, Missense</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009518">New York</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010375">Pedigree</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013628">Talus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D029961">Zebrafish Proteins</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1182012</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2004</Year>
                <Month>Feb</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2004</Year>
                <Month>Apr</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2004</Year>
                <Month>May</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15146389</ArticleId>
            <ArticleId IdType="doi">10.1086/422015</ArticleId>
            <ArticleId IdType="pii">S0002-9297(07)61997-1</ArticleId>
            <ArticleId IdType="pmc">PMC1182012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21381754</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>06</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Apr</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2060-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/jm1011534</ELocationID>
            <Abstract>
                <AbstractText>Twenty-two compounds based on thiazolidine-2,4-dione moiety were synthesized and evaluated for the inhibitory potency on the production of nitric oxide (NO), inducible nitric oxide synthase (iNOS) activity, and the generation of prostaglandin E(2) (PEG(2)). (Z)-N-(3-chlorophenyl)-2-(4-((2,4-dioxothiazolidin-5-ylidene) methyl) phenoxy) acetamide (3I), superior to the commercial anti-inflammatory drug indomethacin, significantly inhibited iNOS activity (IC(50) = 8.66 μM), iNOS-mediated NO, and cyclooxygenase (COX)-2-derived PGE(2) production (IC(50) = 4.16 and 23.55 μM, respectively) on lipopolysaccharide (LPS)-induced RAW 264.7 cells. Docking study revealed that 3I was perfectly docking into the active site of murine iNOS and suppressed the expression of iNOS protein as evidenced by Western blot analysis. At the dose of 50 mg/kg, oral administration of 3I possessed protective properties in both carrageenan-induced paw edema and adjuvant-induced arthritis rat models.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Keyuan Road 4, Gaopeng Street, Chengdu 610041, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Caifeng</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yinghua</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Juan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiang</LastName>
                    <ForeName>Mingli</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Xia</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Zhizhi</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Qinyuan</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jinying</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jincheng</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Neng</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Guangcheng</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Xiaolin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Aihua</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Shengyong</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Yuquan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Lijuan</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>03</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001597">Benzylidene Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2295-31-0</RegistryNumber>
                <NameOfSubstance UI="C089946">2,4-thiazolidinedione</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9000-07-1</RegistryNumber>
                <NameOfSubstance UI="D002351">Carrageenan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.39</RegistryNumber>
                <NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.1</RegistryNumber>
                <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K7Q1JQR04M</RegistryNumber>
                <NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001169">Arthritis, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001597">Benzylidene Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002351">Carrageenan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004487">Edema</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020128">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D052247">Nitric Oxide Synthase Type II</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011487">Protein Conformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045162">Thiazolidinediones</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm1011534</ArticleId>
            <ArticleId IdType="pubmed">21381754</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12384171</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-3908</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Neuropharmacology</Title>
                <ISOAbbreviation>Neuropharmacology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.</ArticleTitle>
            <Pagination>
                <MedlinePgn>857-67</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cannabis is the most widely consumed illicit drug and its consumption is currently associated with tobacco, which contains another psychoactive compound, namely nicotine. Interactions between cannabinoids and other drugs of abuse, such as opioids, have been previously reported. The aim of the present study was to evaluate the possible role of CB1 cannabinoid receptor in responses induced by acute and repeated nicotine administration by using knockout mice lacking the CB1 cannabinoid receptor and their wild-type littermates. Acute nicotine (0.5, 1, 3 and 6 mg/kg, sc) administration decreased locomotor activity and induced antinociceptive responses in the tail-immersion and the hot-plate test, in wild-type animals. The antinociceptive effects in the tail-immersion test were significantly enhanced in CB1 knockout mice. In wild-type mice nicotine (0.5 mg/kg, sc) produced a significant rewarding effect, as measured by a conditioned place preference paradigm. This response was absent in CB1 knockout mice. Finally, a model of mecamylamine-induced abstinence in chronic nicotine-treated mice (10 mg/kg/day, sc) was developed. Mecamylamine (1 and 2 mg/kg, sc) precipitated several somatic signs of nicotine withdrawal in wild-type dependent mice. However, no difference in the severity of nicotine withdrawal was observed in CB1 knockout mice. These results demonstrate that some acute effects and motivational responses elicited by nicotine can be modulated by the endogenous cannabinoid system and support the existence of a physiological interaction between these two systems.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Castañé</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratori de Neurofarmacologia, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, C/ Dr Aiguader, 80, 08003 Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valjent</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ledent</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parmentier</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maldonado</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valverde</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Neuropharmacology</MedlineTA>
            <NlmUniqueID>0236217</NlmUniqueID>
            <ISSNLinking>0028-3908</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018733">Nicotinic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043882">Receptors, Cannabinoid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>54-11-5</RegistryNumber>
                <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6EE945D3OK</RegistryNumber>
                <NameOfSubstance UI="D008464">Mecamylamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000700">Analgesics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003216">Conditioning, Operant</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006358">Hot Temperature</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007101">Immersion</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008464">Mecamylamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018722">Nicotinic Agonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018733">Nicotinic Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043882">Receptors, Cannabinoid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011955">Receptors, Drug</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012201">Reward</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12384171</ArticleId>
            <ArticleId IdType="pii">S0028390802001181</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19027022</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-8584</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of molecular and cellular cardiology</Title>
                <ISOAbbreviation>J. Mol. Cell. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress?</ArticleTitle>
            <Pagination>
                <MedlinePgn>225-33</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yjmcc.2008.10.013</ELocationID>
            <Abstract>
                <AbstractText>Sarcolemmal Na(+)/H(+) exchanger (NHE) activity, which is provided by the NHE isoform 1 (NHE1), has been implicated in ischemia/reperfusion-induced myocardial injury in animal models and humans, on the basis of studies with pharmacological NHE1 inhibitors. We generated a transgenic (TG) mouse model with cardiac-specific over-expression of NHE1 to determine whether this would be sufficient to increase myocardial susceptibility to ischemia/reperfusion-induced injury. TG mouse hearts exhibited increased sarcolemmal NHE activity and normal morphology and function. Surprisingly, they also showed reduced susceptibility to ischemia/reperfusion-induced injury, as reflected by improved functional recovery and smaller infarcts. Such protection was sustained in the presence of NHE1 inhibition with zoniporide, indicating a mechanism that is independent of sarcolemmal NHE activity. Immunoblot analysis revealed accumulation of immature NHE1 protein as well as marked upregulation of both cytoprotective (78/94 kDa glucose-regulated proteins, calreticulin, protein disulfide isomerase) and pro-apoptotic (C/EBP homologous protein) components of the endoplasmic reticulum (ER) stress response in TG myocardium. With increasing age, NHE1 TG mice exhibited increased myocyte apoptosis, developed left ventricular contractile dysfunction, underwent cardiac remodelling and died prematurely. Our findings indicate that: (1) Cardiac-specific NHE1 over-expression induces the ER stress response in mouse myocardium, which may afford protection against ischemia/reperfusion-induced injury despite increased NHE activity; (2) Ageing NHE1 TG mice exhibit myocyte apoptosis, cardiac remodelling and failure, likely as a result of sustained ER stress; (3) The pluripotent effects of the ER stress response may confound studies that are based on the chronic over-expression of complex proteins in myocardium.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cook</LastName>
                    <ForeName>Alexandra R</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cardiovascular Division, King's College London, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bardswell</LastName>
                    <ForeName>Sonya C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pretheshan</LastName>
                    <ForeName>Subashini</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dighe</LastName>
                    <ForeName>Kushal</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanaganayagam</LastName>
                    <ForeName>Gajen S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jabr</LastName>
                    <ForeName>Rita I</ForeName>
                    <Initials>RI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merkle</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marber</LastName>
                    <ForeName>Michael S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engelhardt</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Avkiran</LastName>
                    <ForeName>Metin</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>British Heart Foundation</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Mol Cell Cardiol</MedlineTA>
            <NlmUniqueID>0262322</NlmUniqueID>
            <ISSNLinking>0022-2828</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017923">Sodium-Hydrogen Antiporter</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8841R2UJPG</RegistryNumber>
                <NameOfSubstance UI="C424422">zoniporide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004721">Endoplasmic Reticulum</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000469">parasitology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006146">Guanidines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D032342">Muscle Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017202">Myocardial Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017923">Sodium-Hydrogen Antiporter</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0022-2828(08)01363-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2008.10.013</ArticleId>
            <ArticleId IdType="pubmed">19027022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19066630</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>3</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2008</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e3898</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0003898</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine involved in cystitis and a non-cognate ligand of the chemokine receptor CXCR4 in vitro. We studied whether CXCR4-MIF associations occur in rat bladder and the effect of experimental cystitis.</AbstractText>
                <AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Twenty male rats received saline or cyclophosphamide (40 mg/kg; i.p.; every 3(rd) day) to induce persistent cystitis. After eight days, urine was collected and bladders excised under anesthesia. Bladder CXCR4 and CXCR4-MIF co-localization were examined with immunhistochemistry. ELISA determined MIF and stromal derived factor-1 (SDF-1; cognate ligand for CXCR4) levels. Bladder CXCR4 expression (real-time RTC-PCR) and protein levels (Western blotting) were examined. Co-immunoprecipitations studied MIF-CXCR4 associations.Urothelial basal and intermediate (but not superficial) cells in saline-treated rats contained CXCR4, co-localized with MIF. Cyclophosphamide treatment caused: 1) significant redistribution of CXCR4 immunostaining to all urothelial layers (especially apical surface of superficial cells) and increased bladder CXCR4 expression; 2) increased urine MIF with decreased bladder MIF; 3) increased bladder SDF-1; 4) increased CXCR4-MIF associations.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data demonstrate CXCR4-MIF associations occur in vivo in rat bladder and increase in experimental cystitis. Thus, CXCR4 represents an alternative pathway for MIF-mediated signal transduction during bladder inflammation. In the bladder, MIF may compete with SDF-1 (cognate ligand) to activate signal transduction mediated by CXCR4.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vera</LastName>
                    <ForeName>Pedro L</ForeName>
                    <Initials>PL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bay Pines VA Healthcare System, Research &amp; Development (151), Bay Pines, Florida, USA. pvera@health.usf.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iczkowski</LastName>
                    <ForeName>Kenneth A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xihai</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meyer-Siegler</LastName>
                    <ForeName>Katherine L</ForeName>
                    <Initials>KL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK075059</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008263">Macrophage Migration-Inhibitory Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7647-14-5</RegistryNumber>
                <NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2001 May 1;166(9):5749-54</RefSource>
                <PMID Version="1">11313418</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Inflamm Bowel Dis. 2008 Jul;14(7):1000-11</RefSource>
                <PMID Version="1">18452220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiol Genomics. 2002;9(1):5-13</RefSource>
                <PMID Version="1">11948286</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2002 Jul;123(1):256-70</RefSource>
                <PMID Version="1">12105854</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2003 Jun 2;197(11):1467-76</RefSource>
                <PMID Version="1">12782713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Interferon Cytokine Res. 2004 Jan;24(1):55-63</RefSource>
                <PMID Version="1">14980085</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2004 Apr;171(4):1698-703</RefSource>
                <PMID Version="1">15017269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G844-50</RefSource>
                <PMID Version="1">14684377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Neurosci. 2003 Aug 8;4:17</RefSource>
                <PMID Version="1">12908877</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2004 Oct;172(4 Pt 1):1504-9</RefSource>
                <PMID Version="1">15371880</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lab Invest. 1967 Jan;16(1):44-65</RefSource>
                <PMID Version="1">4164460</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1997 Jun 1;158(11):5514-7</RefSource>
                <PMID Version="1">9164975</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunology. 1999 Sep;98(1):36-41</RefSource>
                <PMID Version="1">10469231</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1961 Dec;21:1577-89</RefSource>
                <PMID Version="1">14486208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Urol. 2005 Jan;47(1):111-7</RefSource>
                <PMID Version="1">15582259</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2005 Feb;173(2):615-20</RefSource>
                <PMID Version="1">15643275</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G316-26</RefSource>
                <PMID Version="1">15358596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2005 Jul;174(1):338-43</RefSource>
                <PMID Version="1">15947686</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2005 Aug 12;19(12):1257-65</RefSource>
                <PMID Version="1">16052080</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Feb 9;354(6):610-21</RefSource>
                <PMID Version="1">16467548</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Res. 2006 Feb;16(2):162-8</RefSource>
                <PMID Version="1">16474429</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2006 Apr;175(4):1523-8</RefSource>
                <PMID Version="1">16516040</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2006 Jun 15;107(12):4807-16</RefSource>
                <PMID Version="1">16484589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Auton Neurosci. 2006 Jun 30;126-127:380-9</RefSource>
                <PMID Version="1">16651033</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2007 Mar;26(3):281-5</RefSource>
                <PMID Version="1">17376392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2007 Apr;177(4):1568-72</RefSource>
                <PMID Version="1">17382780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2007 May;13(5):587-96</RefSource>
                <PMID Version="1">17435771</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2007 Jun;21(6):1267-80</RefSource>
                <PMID Version="1">17389748</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Behav Immun. 2007 Jul;21(5):581-91</RefSource>
                <PMID Version="1">17292584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lab Invest. 2007 Aug;87(8):807-17</RefSource>
                <PMID Version="1">17572689</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2007 Aug 2;26(35):5046-59</RefSource>
                <PMID Version="1">17310986</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pain. 2007;3:38</RefSource>
                <PMID Version="1">18076762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Inflamm Res. 2008 Feb;57(2):45-50</RefSource>
                <PMID Version="1">18288453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Biol Med (Maywood). 2008 May;233(5):620-6</RefSource>
                <PMID Version="1">18375833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2008 Apr 23;28(17):4488-500</RefSource>
                <PMID Version="1">18434527</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2001 Jul 15;21(14):5027-35</RefSource>
                <PMID Version="1">11438578</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054377">Chemokine CXCL12</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003556">Cystitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008263">Macrophage Migration-Inhibitory Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001743">Urinary Bladder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019459">Urothelium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2588654</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0003898</ArticleId>
            <ArticleId IdType="pubmed">19066630</ArticleId>
            <ArticleId IdType="pmc">PMC2588654</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16111706</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0022-510X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>238</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Nov</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the neurological sciences</Title>
                <ISOAbbreviation>J. Neurol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>93-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report a 36-year-old woman with the occurrence of painful focal seizures of her left hand and the left leg. She also had focal motor seizures at the left corner of her mouth. The duration and frequency of the episodes increased over four days from a few seconds once a day to frequent intervals lasting more than four hours at a time. The symptoms appeared one day after start of the treatment with fluvastatin (40 mg) administered in order to diminish the endothelial activation induced by antiphospholipid antibodies (aPL). The patient suffered from severe manifestations of the antiphospholipid syndrome (APS) including Catastrophic Antiphospholipid Syndrome (CAPS, Asherson's syndrome). In this case a single 40 mg dose of oral fluvastatin was linked to seizures. After discontinuation of this treatment, the seizures immediately disappeared and the patient fully recovered without evidence of permanent neurological damage. This data links statins to seizures in patients with compromised blood brain barrier such as APS.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Miesbach</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine III, University Hospital, Johann Wolfgang Goethe-University, Theodor-Stern Kai 7, 60590 Frankfurt/Main, Germany. miesbach@em.uni-frankfurt.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chapman</LastName>
                    <ForeName>Joab</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scharrer</LastName>
                    <ForeName>Inge</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>08</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Neurol Sci</MedlineTA>
            <NlmUniqueID>0375403</NlmUniqueID>
            <ISSNLinking>0022-510X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005229">Fatty Acids, Monounsaturated</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4L066368AS</RegistryNumber>
                <NameOfSubstance UI="C065180">fluvastatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016736">Antiphospholipid Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004828">Epilepsies, Partial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005229">Fatty Acids, Monounsaturated</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0022-510X(05)00226-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jns.2005.06.008</ArticleId>
            <ArticleId IdType="pubmed">16111706</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6105291</PMID>
        <DateCreated>
            <Year>1980</Year>
            <Month>10</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1980</Year>
            <Month>10</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0140-6736</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>8186</Issue>
                    <PubDate>
                        <Year>1980</Year>
                        <Month>Jul</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lancet</Title>
                <ISOAbbreviation>Lancet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combined treatment of severe intractable hypertension with captopril and diuretic.</ArticleTitle>
            <Pagination>
                <MedlinePgn>105-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The converting-enzyme inhibitor, captopril, in a dose of 450 mg daily, was given together with a diuretic to eleven patients with severe hypertension unresponsive to previous therapy. Sustained control of blood pressure was achieved. Plasma angiotensin II and aldosterone fell significantly, whereas plasma active and total renin, and blood-angiotensin-I concentrations increased. Adverse effects included temporary taste disturbance, tachycardia, nephrotic syndrome, and possible drug-induced Guillain-Barré neuropathy. The combination of captopril and diuretic is thus very effective in controlling refractory hypertension. However, because of the frequency and severity of side-effects it should probably be used only in patients whose blood pressure has previously been uncontrolled by other means.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Atkinson</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lever</LastName>
                    <ForeName>A F</ForeName>
                    <Initials>AF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robertson</LastName>
                    <ForeName>J I</ForeName>
                    <Initials>JI</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Lancet</MedlineTA>
            <NlmUniqueID>2985213R</NlmUniqueID>
            <ISSNLinking>0140-6736</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9DLQ4CIU6V</RegistryNumber>
                <NameOfSubstance UI="D011392">Proline</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9G64RSX1XD</RegistryNumber>
                <NameOfSubstance UI="D002216">Captopril</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002216">Captopril</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004232">Diuretics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009404">Nephrotic Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011129">Polyradiculoneuropathy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011392">Proline</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013610">Tachycardia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013651">Taste Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1980</Year>
                <Month>7</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1980</Year>
                <Month>7</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1980</Year>
                <Month>7</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6105291</ArticleId>
            <ArticleId IdType="pii">S0140-6736(80)90001-X</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
